IHL - INCANNEX - HOLDERS RESEARCH, page-349

Some might say its a bold claim to simply say it will work - well....no....the results are already on the board so the obvious question on the back of this post is what can you back that opinion up with?

as an investor do the research and discover that Incannex is using 2 already trialed and approved FDA drugs, combining them to gain synergistic advantage in the treatment - and patent advantage in the 'novel and inventive' approach = $$$$$$
( acetazolamide is also FDA approved as a drug in its own right......when i suggest the 'brilliance of the BOD - this is the reference point....already trialed and approved drug candidates significantly reduces time and cost to commercialisation.... )

So
a proof of concept study was conducted in 2013 with well tolerated outcomes and a safety profile that suggested further work using dronabinol as a treatment for osa was warranted

link
Proof of concept trial of dronabinol in obstructive sleep apnea - PubMed (nih.gov)




as highlighted one of the lead investigators/ principal analysts was David W Carley....bit of a leader in the field as far as dronabinol / OSA research outcomes goes.....plenty on the web for investors to find to back this up....

these guys picked up on these efficacous outcomes and Dr Davids work and....


Dronabinol for the Treatment of Obstructive Sleep Apnea (respirerx.com)




look at the results ....stunning stuff

important to read this post as additional material to the previous for correct context

the more investors follow this path the more they will come to realise the incredible opportunity about to unfold here in 2022

self confessed doubters and 'important other opinion posters' have not done thorough research in the work Incannex is undertaking and the market opportunity they are attempting to leverage - it becomes obvious once you have this background context and removes 95% of the uncertainty imo.....that said, of course there is risk involved - its the nature of a startup but that risk 'punch list' shouldn't is only a key research driver in my experience - it should be further reason to dig for the underpinning context to what Incannex is developing and attempting to bring to market

plenty on the web - you'll find similar efficacy and trial work research outcomes around FDA approved drug acetazolamide.....worth a look id'e suggest

looking forward to the news flow obviously